Uveitis Treatment Market by Drug Class (Corticosteroids, Immunosuppressant, Monoclonal antibodies, Antibiotics, Antivirals, Antifungal, Analgesics) and Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Panuveitis) Cause (Infectious Uveitis, Non-Infectious Uveitis), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Others)- Geography.     

Uveitis Treatment Market size was valued at 581 million in 2022 and is poised to grow at a significant CAGR of 5.7% from 2023 to 2029. Market players are developing novel molecules that can treat uveitis conditions in order to enhance their sales revenue. Companies are focusing on the development of the various drugs in the treatment of the uveitis. For instance, Aurinia Pharmaceuticals Inc. developing Luvenia, a calcineurin inhibitor for the treatment of noninfectious uveitis. Recently it has completed its phase-II clinical trials. Similarly, other pipeline drugs such as EMEA, DE-109, Gevokizumab, Peptide B27PD are being developed by different companies. Considering the aforementioned factors global uveitis treatment market is expected to grow at the significant rate during the forecast period. Uveitis is the term that describes a group of inflammatory diseases that affect the eye and produces swelling. Uveitis can reduce sight and may cause vision loss. Causes of uveitis include infections such as brucellosis, leptospirosis, syphilis, tuberculosis, autoimmune diseases such as sarcoidosis, Crohn's disease, multiple sclerosis, arthritis, ankylosing spondylitis, and psoriatic arthritis. In addition, uveitis is also caused by drugs such as rifabutin and moxifloxacin. Uveitis affects uvea, lens, retina, optic nerve, and vitreous. Uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis and pan-uveitis based on part of inflammation.